3D. M. Nachbaur,M. Herold,A. Maneschg,H. Huber. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters[J] 1991,Annals of Hematology(2-3):54～58
4Thérèse Commes,Bernard Klein,Michel Jourdan,Gisèle Clofent,Frédéric Houssiau,Jean Grenier,Régis Bataille. The defect in peripheral blood B-cell activation in patients with multiple myeloma is not due to a deficiency in the production of B-cell growth and differentiation factors[J] 1989,Journal of Clinical Immunology(1):65～73
5Tadamitsu Kishimoto. B-cell stimulatory factors (BSFs): Molecular structure, biological function, and regulation of expression[J] 1987,Journal of Clinical Immunology(5):343～355
6D. M. Nachbaur,M. Herold,A. Maneschg,H. Huber. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters[J] 1991,Annals of Hematology(2-3):54～58
7Thérèse Commes,Bernard Klein,Michel Jourdan,Gisèle Clofent,Frédéric Houssiau,Jean Grenier,Régis Bataille. The defect in peripheral blood B-cell activation in patients with multiple myeloma is not due to a deficiency in the production of B-cell growth and differentiation factors[J] 1989,Journal of Clinical Immunology(1):65～73
8Tadamitsu Kishimoto. B-cell stimulatory factors (BSFs): Molecular structure, biological function, and regulation of expression[J] 1987,Journal of Clinical Immunology(5):343～355
